Secondary cytoreductive surgery followed by olaparib tablets as maintenance therapy in patients with BRCA mutated recurrent ovarian cancer: A multi-center retrospective study
Menée à l'aide de données portant sur 623 patientes atteintes d'un cancer épithélial de l'ovaire avec mutation au niveau des gènes BRCA, cette étude analyse la survie globale et la survie sans progression après une chirurgie cytoréductrice secondaire suivie d'un traitement d'entretien par sels de platine et olaparib
Objective: To evaluate the effect of secondary cytoreductive surgery (SeCRS) followed by platinum-based chemotherapy (PBC) and olaparib tablets as maintenance therapy in patients with BRCA mutated recurrent epithelial ovarian cancer. Methods: This was a retrospective study of a prospective database. We collected information on 623 patients diagnosed with BRCA mutated recurrent epithelial ovarian cancer, all of whom underwent SeCRS followed by PBC in combination with or without olaparib. Overall survival and progression-free survival were measured to evaluate treatment effectiveness. Results: Of the 623 patients recruited, 240 underwent SeCRS plus hyperthermic intraperitoneal chemotherapy followed by PBC and olaparib maintenance therapy (Group A), 248 underwent SeCRS followed by PBC and olaparib maintenance therapy (Group B), and 135 underwent SeCRS followed by PBC only upon recurrence (Group C). The median progression-free survival for Group A was significantly longer than that for Group B (32.5 vs. 24.2 months, P﹤0.001), and Group B was significantly longer than Group C (24.2 vs. 15.1 months, P﹤0.001). The median overall survival for Groups A was significantly longer than that for Group B (71.4 vs. 63.5 months, P﹤0.001), and Group B was significantly longer than Group C (63.5 vs. 47.5 months, P﹤0.001). Conclusions: This study suggested that SeCRS followed by PBC and olaparib maintenance therapy resulted in longer overall survival and progression-free survival than SeCRS followed by PBC only in patients with BRCA mutated recurrent ovarian cancer, especially in patients treated with SeCRS plus hyperthermic intraperitoneal chemotherapy.